The Complete Guide to Targeted Therapies in Oncology: A World Review

Table of Contents

1 Executive Summary

2 Table of Contents

• 2.1 List of Boxes
• 2.2 List of Figures
• 2.3 List of Tables

3 Methodology

4 Introduction to Apoptosis in Oncology

5 Apoptosis Competitive Landscape in Oncology

• 5.1 Countries & Players: Who are In the Lead?
  • 5.1.1 Top 10 Players Dominate The Developmental Pipeline
• 5.2 Deals & Alliances in Apoptosis Drug Development
  • 5.2.1 Review of Deals and Alliances Initiated in 2006
  • 5.2.2 Review of Deals and Alliances Initiated in 2005
  • 5.2.3 Review of Deals and Alliances Initiated in 2004
  • 5.2.4 Review of Deals and Alliances Initiated in 2003
  • 5.2.5 Review of Deals and Alliances Initiated in 2002
  • 5.2.6 Review of Deals and Alliances Initiated in 2001

6 Approved Apoptopic Cancer Drugs: Performance

7 Target Analysis in Apoptosis

• 7.1 Targets of Late Stage Apoptopic Drugs in Development
  • 7.1.1 B-cell CLL/lymphoma 2
  • 7.1.2 Caspase 3
  • 7.1.3 CD4 molecule
  • 7.1.4 Cytosolic ovarian carcinoma antigen 1
  • 7.1.5 Eukaryotic translation elongation factor 2
  • 7.1.6 Farnesyltransferase, CAAX box, alpha
  • 7.1.7 Fc fragment of IgE
  • 7.1.8 Histone deacetylase 1
  • 7.1.9 Histone deacetylase 2
  • 7.1.10 Interleukin 13 receptor, alpha 1
  • 7.1.11 Phosphodiesterase 2A, cGMP-stimulated
  • 7.1.12 Phosphodiesterase 5A, cGMP-specific
  • 7.1.13 Protein kinase C, beta 1
  • 7.1.14 Steroid 5-alpha-reductase, alpha polypeptide 1
  • 7.1.15 Topoisomerase (DNA) I
  • 7.1.16 Topoisomerase (DNA) II alpha
  • 7.1.17 Tubulin, beta polypeptide
  • 7.1.18 p53 protein
• 7.2 Apoptopic Drugs and Their Targets According to Top 5 Cancer Indications
  • 7.2.1 Targets in Breast Cancer
  • 7.2.2 Targets in Leukemia
  • 7.2.3 Targets in Lung Cancer
  • 7.2.4 Targets in Lymphoma
  • 7.2.5 Targets in Prostate Cancer

8 Apoptopic Drugs in Development: By Major Indications

• 8.1 General Drug Developmental Overview
  • 8.1.1 Apoptopic Drugs in Phase III Clinical Development
  • 8.1.2 Failed Apoptopic Drugs in Oncology
• 8.2 Progress Analysis - Breast Cancer
  • 8.2.1 Phase I Clinical Development
  • 8.2.2 Phase II Clinical Development
  • 8.2.3 Phase III Clinical Development
• 8.3 Progress Analysis - Leukemia
  • 8.3.1 Phase I Clinical Development
  • 8.3.2 Phase II Clinical Development
  • 8.3.3 Phase III Clinical Development
• 8.4 Progress Analysis - Lung Cancer
  • 8.4.1 Phase I Clinical Development
  • 8.4.2 Phase II Clinical Development
  • 8.4.3 Phase III Clinical Development
• 8.5 Progress Analysis - Lymphoma
  • 8.5.1 Phase I Clinical Development
  • 8.5.2 Phase II Clinical Development
  • 8.5.3 Phase III Clinical Development
• 8.6 Progress Analysis - Prostate Cancer
  • 8.6.1 Phase I Clinical Development
  • 8.6.2 Phase II Clinical Development
  • 8.6.3 Phase III Clinical Development

9 Protein Kinase Inhibitors

• 9.1 Rationale for Development of Kinase Inhibitors in Oncology
• 9.2 Protein Kinase Targets - A Growing Family
• 9.3 Challenges in Protein Kinase Drug Discovery
  • 9.3.1 Enabling Structure-Based Drug Design is the Key
  • 9.3.2 Specific Kinase Inhibitors without Kinase Profiling?
• 9.4 Drugs according to Target
  • 9.4.1 Cyclin-dependent Kinase Target Inhibitors
  • 9.4.2 Aurora Kinase Target Inhibitors
  • 9.4.3 Cell Cycle Checkpoint Target Controls Inhibitors
  • 9.4.4 Tyrosine Kinase Receptor Inhibitors
  • 9.4.5 Other Serine/Threonine Kinase Target Inhibitors
• 9.5 Dual or Multiple Kinase Inhibitor Analysis
  • 9.5.1 Presentation of Drugs Targeting A to F Kinases
  • 9.5.2 Presentation of Drugs Targeting G to T Kinases
• 9.6 Targets According to Indication
  • 9.6.1 Breast Cancer
  • 9.6.2 Prostate Cancer: What Cannot be Found in the ' Groins' ?
  • 9.6.3 Lung Cancer: A Need for Improved Survival Rates
  • 9.6.4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but There are Others
  • 9.6.5 Leukemia: Show Me the Power of PKI
  • 9.6.6 Melanoma
  • 9.6.7 Lymphoma: We Are In
• 9.7 Growing Competition in the Field
• 9.8 Big Pharma Outlook: The Race is On
  • 9.8.1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors
  • 9.8.2 AstraZeneca - Wheeling and Dealing
  • 9.8.3 Pfizer' s Long Look at OSI Pharmaceuticals
  • 9.8.4 GlaxoSmithKline Gains Momentum
• 9.9 Strategic Deals Creating Competitive Edge
  • 9.9.1 Mergers
  • 9.9.2 Astex - the PKI Switchboard
  • 9.9.3 Big Pharma' s Darling
• 9.10 Current Protein Kinase Inhibitors in Therapy
  • 9.10.1 Mechanism, Target and Developmental History
  • 9.10.2 Approvals: Indications & Markets
• 9.11 Protein Kinase Inhibitors in Drug Development - A Progress Analysis
  • 9.11.1 Progress Analysis - Breast Cancer
  • 9.11.2 Progress Analysis - Prostate Cancer
  • 9.11.3 Progress Analysis - Lung Cancer
  • 9.11.4 Progress Analysis - Colorectal Cancer
  • 9.11.5 Progress Analysis - Leukemia
  • 9.11.6 Progress Analysis - Melanoma
  • 9.11.7 Progress Analysis - Lymphoma

10 Anti-Angiogenesis & Vascular Targeting

• 10.1 Neoplastic Angiogenesis & Tumor Vasculature
  • 10.1.1 Tumor Vasculature
  • 10.1.2 The Current Model of Sprouting Angiogenesis
• 10.2 Main Angiogenic Factors
  • 10.2.1 Vascular Endothelial Growth Factor
  • 10.2.2 The Angiopoietins and Platelet Derived Growth Factor
  • 10.2.3 Integrins in Angiogenesis
  • 10.2.4 Inhibitors of Angiogenesis
• 10.3 Vascular Targeting Agents
• 10.4 Vascular Disruptive Agents
• 10.5 Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology
• 10.6 Countries & Players: Who are In the Lead?
  • 10.6.1 Top 10 Players Dominate The Developmental Pipeline
• 10.7 Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
  • 10.7.1 Review of Deals and Alliances Initiated in 2005
  • 10.7.2 Review of Deals and Alliances Initiated in 2004
  • 10.7.3 Review of Deals and Alliances Initiated in 2003
• 10.8 Approved Anti-Angiogenic Cancer Drugs: Performance
• 10.9 Target Analysis in Anti-Angiogenesis and Vascular Targeting
• 10.10 Targets of Late Stage Anti-Angiogenic Drugs in Development
  • 10.10.1 Drugs with Epidermal Growth Factor Receptor as a Target
  • 10.10.2 Drugs with FMS-related Tyrosine Kinase 1 as a Target
  • 10.10.3 Drugs with FMS-related Tyrosine Kinase 4 as a Target
  • 10.10.4 Drugs with Kinase Insert Domain Receptor as a Target
  • 10.10.5 Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
  • 10.10.6 Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
  • 10.10.7 Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
  • 10.10.8 Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
  • 10.10.9 Drugs with Protein Kinase C, beta 1 as a Target
  • 10.10.10 Drugs with Ret Proto-Oncogene as a Target
  • 10.10.11 Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
  • 10.10.12 Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
  • 10.10.13 Drugs with Vascular Endothelial Growth Factor as a Target
• 10.11 Anti-Angiogenic Drugs and Their Targets According to Top 5 Cancer Indications
  • 10.11.1 Targets in Breast Cancer
  • 10.11.2 Targets in Colorectal Cancer
  • 10.11.3 Targets in Lung Cancer
  • 10.11.4 Targets in Prostate Cancer
  • 10.11.5 Targets in Renal Cancer
• 10.12 Anti-angiongenesis and Vascular Targeting Drugs in Development: By Major Indications
• 10.13 General Drug Developmental Overview
• 10.14 Progress Analysis - Breast Cancer
  • 10.14.1 Phase I Clinical Development
  • 10.14.2 Phase II Clinical Development
  • 10.14.3 Phase III Clinical Development
• 10.15 Progress Analysis - Colorectal Cancer
  • 10.15.1 Phase I Clinical Development
  • 10.15.2 Phase II Clinical Development
  • 10.15.3 Phase III Clinical Development
• 10.16 Progress Analysis - Lung Cancer
  • 10.16.1 Phase I Clinical Development
  • 10.16.2 Phase II Clinical Development
  • 10.16.3 Phase III Clinical Development
• 10.17 Progress Analysis - Prostate Cancer
  • 10.17.1 Phase I Clinical Development
  • 10.17.2 Phase II Clinical Development
  • 10.17.3 Phase III Clinical Development
• 10.18 Progress Analysis - Renal Cancer
  • 10.18.1 Phase I Clinical Development
  • 10.18.2 Phase II Clinical Development
  • 10.18.3 Phase III Clinical Development

11 Immunotherapy in Oncology

• 11.1 Vaccine Strategies: Challenges & Opportunities
• 11.2 Key Antibody Developmental Strategies

12 Competitive Landscape in Cancer Vaccines

• 12.1 Countries & Players: Who are In the Lead?
  • 12.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
  • 12.1.2 Approved Cancer Vaccine Drugs: Performance
• 12.2 Deals & Alliances in Cancer Vaccines
  • 12.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
  • 12.2.2 Deals in Prostate Cancer
  • 12.2.3 Deals in Breast Cancer
  • 12.2.4 Deals in Leukemia & Lymphoma
  • 12.2.5 Drug Delivery Deals in Cancer Vaccines
  • 12.2.6 Adjuvant Deals

13 Antibody Deals on the Rise

• 13.1 Antibody Deals in Phase III
  • 13.1.1 Deal Situation: MDX 010
  • 13.1.2 Deal Situation: WX G250
  • 13.1.3 Deal Situation: Zanolimumab
• 13.2 Antibody Deals in Phase II
  • 13.2.1 Deal Situation: Mapatumumab
  • 13.2.2 Deal Situation: GCR 3888
  • 13.2.3 Deal Situation: MDX 070
  • 13.2.4 Deal Situation: CDP 860
  • 13.2.5 Deal Situation: Tru-Scint OV
  • 13.2.6 Deal Situation: SC 1
  • 13.2.7 Deal Situation: PRO 70769
  • 13.2.8 Deal Situation: XR 303
  • 13.2.9 Deal Situation: HumaRAD-HN

14 Tumor Antigens

• 14.1 Tumor Antigens: General Comments
• 14.2 Antigen Discovery
  • 14.2.1 Classical Immunology Approach
  • 14.2.2 The Reverse Immunology Approach
  • 14.2.3 Company Platforms
• 14.3 Specific Antigen Processing Technologies Increasing Antigen Presentation

15 Immunomodulators & Adjuvants in Cancer Vaccines

• 15.1 Overview
• 15.2 Cytokines
  • 15.2.1 Vaccines in Combination with Interleukin-2
  • 15.2.2 Tumor Necrosis Factor
  • 15.2.3 Interferons
• 15.3 Adjuvants
• 15.4 Other Immunomodulating Strategies
  • 15.4.1 An Immune Response Modifying Protein
  • 15.4.2 Immunostimulatory DNA
  • 15.4.3 Ex Vivo Stimulated Immune Cells
  • 15.4.4 Fusion Protein Gain Potent Immune Response
  • 15.4.5 Macrophage and Natural Killer Cells Activation
  • 15.4.6 Selective Suppression of the Immune System to An Antigen
  • 15.4.7 TAP Technology

16 Cancer Vaccine Delivery

• 16.1 Viral Delivery
  • 16.1.1 Introduction
  • 16.1.2 Viral Constructs Put into Use
• 16.2 Bacterias
• 16.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
  • 16.3.1 Introduction
  • 16.3.2 Cell Therapy Strategies
• 16.4 Synthetic Delivery Systems & Strategies
  • 16.4.1 Introduction
  • 16.4.2 Biotransport™
  • 16.4.3 Biotype®vector
  • 16.4.4 DNAVax Gene Delivery System
  • 16.4.5 FusitAb™
  • 16.4.6 GeneDrug™
  • 16.4.7 Molecular Conjugates
  • 16.4.8 Naked DNA Delivery
  • 16.4.9 PVLP Technology
  • 16.4.10 Sphingosomal Drug Delivery Technology
  • 16.4.11 STEALTH
  • 16.4.12 Failed Liposomal Systems

17 New Approaches in Antibody Delivery and Design - The Next Generation

• 17.1 How to Make Them Smaller and Different?
• 17.2 Biomaterials in Sustained Delivery Applications
  • 17.2.1 Implants
• 17.3 Gene delivery - the Future?
  • 17.3.1 Delivery Vehicles for DNA
  • 17.3.2 Gene Delivery in Commercialization

18 Cancer Vaccines in Development: By Major Indications

• 18.1 General Oncology Overview
• 18.2 Progress Analysis - Melanoma
• 18.3 Progress Analysis - Breast Cancer
• 18.4 Progress Analysis - Prostate Cancer
• 18.5 Progress Analysis - Lung Cancer
• 18.6 Progress Analysis - Colorectal Cancer
• 18.7 Progress Analysis - Cervical Cancer

19 Antibodies in Clinical Development

• 19.1.1 Prostate Cancer Therapeutics
• 19.1.2 Breast Cancer Therapeutics
• 19.1.3 Colorectal Cancer Therapeutics
• 19.1.4 Melanoma Therapeutics
• 19.1.5 Hematological Cancers Therapeutics

• 19.2 Antibodies in Phase III Clinical Development
  • 19.2.1 Progress Analysis: IGN 101
  • 19.2.2 Progress Analysis: MDX 010
  • 19.2.3 Progress Analysis: ONYVAX 105
  • 19.2.4 Progress Analysis: Ovarex
  • 19.2.5 Progress Analysis: Panitumumab
  • 19.2.6 Progress Analysis: RENCAREX
  • 19.2.7 Progress Analysis: Nimotuzumab
  • 19.2.8 Progress Analysis: TransMID
  • 19.2.9 Progress Analysis: Lintuzumab
  • 19.2.10 Progress Analysis: Zanolimumab
• 19.3 Antibodies in Phase II Clinical Development
  • 19.3.1 Progress Analysis: ABT-510
  • 19.3.2 Progress Analysis: BB 10901
  • 19.3.3 Progress Analysis: CP 675206
  • 19.3.4 Progress Analysis: CNTO-328
  • 19.3.5 Progress Analysis: Ecromeximab
  • 19.3.6 Progress Analysis: EMD 273063
  • 19.3.7 Progress Analysis: WX-G250RIT
  • 19.3.8 Progress Analysis: HGS-ETR1
  • 19.3.9 Progress Analysis: HuMax-CD20
  • 19.3.10 Progress Analysis: HuMax-EGFr
  • 19.3.11 Progress Analysis: Galiximab
  • 19.3.12 Progress Analysis: PROXINIUM
  • 19.3.13 Progress Analysis: RAV12
  • 19.3.14 Progress Analysis: SGN-15
  • 19.3.15 Progress Analysis: SGN-30
  • 19.3.16 Progression Analysis: VEGF-Trap
  • 19.3.17 Progress Analysis: MEDI 522
  • 19.3.18 Progress Analysis: Volociximab

20 Disclaimer

21 Appendix I: Complete List of Apoptopic Drugs in Development in Oncology

22 Appendix II: Complete List of Angiogenic and Vascular Target Agents in Development in Oncology

23 Company Index

24 Drug Index

List of Boxes

• Box 1: Business & Market - PXD-101
• Box 2: Business & Market - MG-98
• Box 3: Business & Market - VX-680
• Box 4: Business & Market - Ceflatonin
• Box 5: Business & Market - Oblimersen sodium
• Box 6: Business & Market - motexafin gadolinium
• Box 7: Business & Market - 1D09C3
• Box 8: Business & Market - PCK-3145
• Box 9: Business & Market - ME-2
• Box 10: The Power of Ambit' s Kinase Profiling
• Box 11: Summary Terms of the Exelixis Transaction
• Box 12: Nexavar' s Clinical Data That Lead To Its EMEA Approval Myeloma
• Box 13: Thalomid Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
• Box 14: Strong Clinical Data Suggests Approval to Market Avastin For The Treatment of Both Breast Cancer and NSCLC
• Box 15: Avastin Fails to Meet Primary Endpoint in Advanced Pancreatic Cancer
• Box 16: Business & Market - Cilengitide
• Box 17: Business & Market - Exherin
• Box 18: Business & Market - WX-UK1
• Box 19: Business & Market - Combretastatin A-4 phosphate
• Box 20: Business & Market - GCS-100LE
• Box 21: Business & Market - PTK/ZK
• Box 22: Business & Market - AS-1404
• Box 23: Business & Market - Phosphomannopentaose sulfate
• Box 24: Business & Market - Squalamine
• Box 25: Business & Market - talactoferrin alfa
• Box 26: Business & Market - ZD-6474
• Box 27: Business & Market - AP-23573
• Box 28: Business & Market - Volociximab
• Box 29: Business & Market - XL-999
• Box 30: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction
• Box 31: M-VAX - Business & Market Bakground
• Box 32: Gardasil: Business & Market Background
• Box 33: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology
• Box 34: TNF in Cancer Treatments
• Box 35: Marrion' s Drug Delivery Technology
• Box 36: Quick Facts - IGN 101
• Box 37: Quick Facts - MDX 010
• Box 38: Quick Facts - ONYVAX 105
• Box 39: Quick Facts - Ovarex
• Box 40: Quick Facts - Panitumumab
• Box 41: Quick Facts - RENCARNEX
• Box 42: Quick Facts - Nimotuzumab
• Box 43: Quick Facts - RENCARNEX
• Box 44: Quick Facts - Lintuzumab
• Box 45: Quick Facts - Zanolimumab
• Box 46: Quick Facts - ABT-510
• Box 47: Quick Facts - BB 10901
• Box 48: Quick Facts - CP-675206
• Box 49: Quick Facts - CNTO-328
• Box 50: Quick Facts - Ecromeximab
• Box 51: Quick Facts - EMD-273063
• Box 52: Quick Facts - WX-G250RIT
• Box 53: Quick Facts - HGS-ETR1
• Box 54: Quick Facts - HuMax-CD20
• Box 55: Quick Facts - HuMax-EGFr
• Box 56: Quick Facts - Galiximab
• Box 57: Quick Facts - PROXINIUM
• Box 58: Quick Facts - RAV12
• Box 59: Quick Facts -SGN-15
• Box 60: Quick Facts -SGN-30
• Box 61: Quick Facts - VEGF-Trap
• Box 62: Quick Facts - MEDI 522
• Box 63: Quick Facts - Volociximab

List of Figures

• Figure 1: Top 5 Countries in Apoptopic Cancer Research
• Figure 2: Top 10 Companies' Clinical Trial Progress in Apoptopic Drug Development
• Figure 3: Trial Distribution of the Entire Apoptopic Pipeline in Oncology
• Figure 4: Distribution of ApoptopicTrials in Breast Cancer
• Figure 5: Distribution of Apoptopic Drug Trials in Leukemia
• Figure 6: Distribution of Apoptopic Drug Trials in Lung Cancer
• Figure 7: Distribution of Apoptopic Drug Trials in Lymphoma
• Figure 8: Distribution of Apoptopic Drug Trials in Prostate Cancer
• Figure 9: Top 10 PKI Drug Developing Companies
• Figure 10: Clinical Trial Distribution in Breast Cancer for PKI Drugs
• Figure 11: Clinical Trial Distribution in Prostate Cancer for PKI Drugs
• Figure 12: Clinical Trial Distribution in Lung Cancer for PKI Drugs
• Figure 13: Clinical Trial Distribution in Colorectal Cancer for PKI Drugs
• Figure 14: Clinical Trial Distribution in Leukemia for PKI Drugs
• Figure 15: Clinical Trial Distribution in Melanoma for PKI Drugs
• Figure 16: Clinical Trial Distribution in Lymphoma for PKI Drugs
• Figure 17: Establishment of Blood Supply to Tumors
• Figure 18: Sprouting Angiogenesis
• Figure 19: Top 5 Countries in Cancer Angiogenesis and Vascular Targeting Research
• Figure 20: Top 10 Companies' Clinical Trial Progress in Anti-Angiogenesis and Vascular Targeting
• Figure 21: Deals & Alliances in Anti-Angiogenesis and Vascular Targeting 2001-2005
• Figure 22: Annual Sales of Avastin on US and Non US Markets
• Figure 23: Trial Distribution of the Entire Anti-Angiogenic and Vascular Target Agent Field in Oncology
• Figure 24: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Breast Cancer
• Figure 25: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Colorectal
• Figure 26: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Lung Cancer
• Figure 27: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Prostate Cancer
• Figure 28: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Renal Cancer
• Figure 29: Top 10 Countries in Cancer Vaccine Research
• Figure 30: Top 10 Companies' Clinical Trial Progress in Cancer Vaccine
• Figure 31: 2003-2005 Deals & Alliances in Cancer Vaccine
• Figure 32: Distribution of Cancer Vaccine Trials in Melanoma
• Figure 33: Distribution of Cancer Vaccine Trials in Breast Cancer
• Figure 34: Distribution of Cancer Vaccine Trials in Prostate Cancer
• Figure 35: Distribution of Cancer Vaccine Trials in Lung Cancer
• Figure 36: Distribution of Cancer Vaccine Trials in Colorectal Cancer
• Figure 37: Distribution of Cancer Vaccine Trials in Cervical Cancer

List of Tables

• Table 1: Top 10' s Apoptopic Pipeline Drugs
• Table 2: Deals & Alliances in Apoptosis Drug Development in Oncology
• Table 3: Companies with Apoptopic Cancer Drugs on the Market
• Table 4: List of 120 Known Targets in Apoptosis Drug Development
• Table 5: Known Targets of Late Stage Apoptopic Drugs Development
• Table 6: Drugs with Bcl-2 as a Target
• Table 7: Drugs with Casp-3 as a Target
• Table 8: Drugs with CD4 molecule as a Target
• Table 9: Drugs with Cova-1 as a Target
• Table 10: Drugs with Eef-2 as a Target
• Table 11: Drugs with Fnta as a Target
• Table 12: Drugs with Fcer-2 as a Target
• Table 13: Drugs with Hdac-1 as a Target
• Table 14: Drugs with Hdac-2 as a Target
• Table 15: Drugs with IL13-RA1 as a Target
• Table 16: Drugs with Pde-2A as a Target
• Table 17: Drugs with Pde-5A as a Target
• Table 18: Drugs with Prkcb-1 as a Target
• Table 19: Drugs with Srd-5A1 as a Target
• Table 20: Drugs with Top-1 as a Target
• Table 21: Drugs with Top-2A as a Target
• Table 22: Drugs with Top-2A as a Target
• Table 23: Drugs with p53 protein as a Target
• Table 24: Breast Cancer Targets in Apoptopic Drug Development
• Table 25: Leukemia Targets in Apoptopic Drug Development
• Table 26: Lung Cancer Targets in Apoptopic Drug Development
• Table 27: Lymhoma Targets in Apoptopic Drug Development
• Table 28: Prostate Cancer Targets in Apoptopic Drug Development
• Table 29: Top 10 Cancer Indications in Apoptopic Cancer Drugs
• Table 30: Overview of Apoptopic Drugs in Phase III Clinical Development
• Table 31: Recently Ceased or Discountinued Phase I to Phase III Apoptopic Drugs
• Table 32: List of Phase I to Phase III Apoptopic Drugs in Development for Breast Cancer
• Table 33: List of Phase I to Phase III Apoptopic Drugs in Development for Leukemia
• Table 34: List of Phase I to Phase III Apoptopic Drugs in Development for Lung Cancer
• Table 35: List of Phase I to Phase III Apoptopic Drugs in Development for Lymphoma
• Table 36: List of Phase I to Phase III Apoptopic Drugs in Development for Prostate Cancer
• Table 37: Overview of Targets in Commercial Development
• Table 38: Cyclin-dependent Kinase Targets in Development
• Table 39: Aurora Kinase Targets in Development
• Table 40: Cell Cycle Checkpoint Targets in Development
• Table 41: Epidermal Growth Factor Receptor Targets in Development
• Table 42: FMS-like tyrosine kinases and their Synonyms
• Table 43: Fms-related Tyrosine Kinase Targets in Development
• Table 44: Platelet-derived Growth Factor Receptor Targets in Development
• Table 45: Kinase Insert Domain Targets in Development
• Table 46: Drugs in Development Targeting the PI3K/Akt/mTOR pathway
• Table 47: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway
• Table 48: Serine/Threonine Kinase Inhibitors in Development
• Table 49: Protein Kinase Targets in Clinical Trials for Breast Cancer
• Table 50: Protein Kinase Targets in Clinical Trials for Prostate Cancer
• Table 51: Protein Kinase Targets in Clinical Trials for Lung Cancer
• Table 52: Protein Kinase Targets in Clinical Trials for Colorectal Cancer
• Table 53: Protein Kinase Targets in Clinical Trials for Leukemia
• Table 54: Protein Kinase Targets in Clinical Trials for Melanoma
• Table 55: Protein Kinase Targets in Clinical Trials for Lymphoma
• Table 56: Drugs in Therapy - Mechanism & Targets
• Table 57: Current and Developmental History of PKI Drugs in Therapy
• Table 58: Approvals: Indications & Markets
• Table 59: Top 10 Drugs in Terms of Number of Clinical Trials
• Table 60: List of Cancer Indications Targeted by Protein Kinase Inhibitors
• Table 61: PKI Drugs in Development for Breast Cancer
• Table 62: PKI Drugs in Development for Prostate Cancer
• Table 63: PKI Drugs in Development for Lung Cancer
• Table 64: PKI Drugs in Development for Colorectal Cancer
• Table 65: PKI Drugs in Development for Leukemia
• Table 66: PKI Drugs in Development for Melanoma
• Table 67: PKI Drugs in Development for Lymphoma
• Table 68: Top 10' s Anti-angiogenic and Vascular Targeting Pipeline Drugs
• Table 69: Deals & Alliances in 2005
• Table 70: Deals & Alliances in 2004
• Table 71: Deals & Alliances in 2003
• Table 72: Companies with Cancer Anti-angiogenic Drugs on the Market
• Table 73: 2006 Q2 Sales Revlimid and Thalomid
• Table 74: 2006 Q2 Sales of Avastin
• Table 75: List of 75 Known Targets in Ant-angiogenis and Vascular Targeting in Drug Development
• Table 76: Known Targets of Late Stage Anti-Angiogenic Drugs in Development
• Table 77: Drugs with Epidermal Growth Factor Receptor as a Target
• Table 78: Drugs with FMS-related Tyrosine Kinase 1 as a Target
• Table 79: Drugs with FMS-related Tyrosine Kinase 4 as a Target
• Table 80: Drugs with Kinase Insert Domain Receptor as a Target
• Table 81: Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
• Table 82: Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
• Table 83: Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
• Table 84: Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
• Table 85: Drugs with Protein Kinase C, beta 1 as a Target
• Table 86: Drugs with Ret Proto-Oncogene as a Target
• Table 87: Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
• Table 88: Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
• Table 89: Drugs with Vascular Endothelial Growth Factor as a Target
• Table 90: Breast Cancer Targets in Anti-Angiogenic Drug Development
• Table 91: Colorectal Cancer Targets in Anti-Angiogenic Drug Development
• Table 92: Lung Cancer Targets in Anti-Angiogenic Drug Development
• Table 93: Prostate Cancer Targets in Anti-Angiogenic Drug Development
• Table 94: Renal Cancer Targets in Anti-Angiogenic Drug Development
• Table 95: Top 10 Cancer Indications in Anti-Angiogenesis and Vascular Targeting Cancer Drugs
• Table 96: Recent Ceased or Discountinued Phase I to Phase III Anti-angiogenic and Vascular Targeting Drugs
• Table 97: Overview of Drugs in Phase III Clinical Development
• Table 98: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Breast Cancer
• Table 99: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Colorectal Cancer
• Table 100: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Lung Cancer
• Table 101: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Prostate Cancer
• Table 102: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Renal Cancer
• Table 103: Summary of Strategies Enhancing Antibody Function
• Table 104: Companies with Cancer Vaccine Drugs on Market
• Table 105: Antigen Classification
• Table 106: Platforms Used to Improve Antigen Presentation
• Table 107: Cancer Vaccines in Clinical Trials in Combination with Interleukin-2
• Table 108: Adjuvants in Cancer Vaccines
• Table 109: Synthetic Delivery Systems Deployed in Cancer in General and Cancer Vaccines in Particular
• Table 110: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
• Table 111: Drug Delivery Companies with Cancer Focus
• Table 112: FDA Approved Polymer-based Drug Delivery Systems for Cancer
• Table 113: Top 10 Cancer Indications in Non-Antibody Based Cancer Vaccines
• Table 114: Discountinued Phase I to Phase III Cancer Vaccine Drugs
• Table 115: List of Phase I to Phase III Cancer Vaccines in Development for Melanoma
• Table 116: List of Phase I to Phase III Cancer Vaccines in Development for Breast Cancer
• Table 117: List of Phase I to Phase III Cancer Vaccines in Development for Prostate Cancer
• Table 118: List of Phase I to Phase III Cancer Vaccines in Development for Lung Cancer
• Table 119: List of Phase I to Phase III Cancer Vaccines in Development for Colorectal Cancer
• Table 120: List of Phase I to Phase III Cancer Vaccines in Development for Cervical Cancer
• Table 121: Antibody Therapeutics in Prostate Cancer
• Table 122: Antibody Therapeutics in Breast Cancer
• Table 123: Antibody Therapeutics in Colorectal Cancer
• Table 124: Antibody Therapeutics in Melanoma
• Table 125: Antibody Therapeutics in Hematological Cancer
• Table 126: MDX-010' s Collaborative History and Landscape